First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M Meeting Abstract
| Authors: | Tan, D. S. W.; Seto, T.; Leighl, N. B.; Riely, G. J.; Sequist, L. V.; Felip, E.; Wolf, J.; Yang, J. C. H.; Matushansky, I.; Yu, X. L.; Schmitz, S. F. H.; Cui, X. M.; Kim, D. W. |
| Abstract Title: | First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901726 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2015.33.15_suppl.8013 |
| Notes: | Meeting Abstract: 8013 -- Source: Wos |
